Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
| ▸ | DRD3 | P35462 | 4/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD5 | P21918 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18374895 | 0.84 | DRD2 (0.35) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL19948194 | 0.80 | DRD2 (0.41) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL15565904 | 0.78 | DRD2 (0.32) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6934553 | 0.76 | MAPT (0.43) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL23250280 | 0.75 | CXCR2 (0.35) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL29863304 | 0.75 | CXCR2 (0.35) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21620884 | 0.75 | KDM4E (0.42) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrogen Sulfide SCHEMBL27838727 | 0.75 | MAPT (0.42) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6938489 | 0.73 | CYP1A2 (0.43) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2989290 | 0.72 | CA1 (0.44) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783736-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170009137-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170009137-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, BRAF, LEF1 | DRD2 231/4885DRD3 203/4885DRD1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.